
Medical Devices · Nasdaq: DXCM
Dexcom earnings: results, call transcripts & KPI history
2 quarters · fiscal year ends December · next results expected around 11 Feb 2027
Latest: Q3 2026
Dexcom published its CONNECT type 2 trial in NEJM, advancing the case for Medicare coverage of non-insulin users, while moving about half its U.S. base to G7 15 Day.
Dexcom says it took share again in the U.S., with its biggest gains among people with type 2 diabetes, including those not on insulin. It launched a redesigned Stelo app and kept rolling out the G7 15 Day sensor, with pump connectivity now broadly available. The CONNECT randomized trial of type 2 patients not on insulin was published in The New England Journal of Medicine after quarter end. Ireland began commercial production on schedule.
Quarters
KPI history
Fourth quarter worked out from the annual figure.
Data
| Q4 2024 | $1.1B * |
| Q1 2025 | $1.0B |
| Q2 2025 | $1.2B |
| Q3 2025 | $1.2B |
| Q4 2025 | $1.3B * |
| Q1 2026 | $1.2B |
| Q2 2026 | $1.3B |
| Q3 2026 | $1.3B |
Data
| Q1 2025 | $0.27 |
| Q2 2025 | $0.45 |
| Q3 2025 | $0.70 |
| Q1 2026 | $0.51 |
| Q2 2026 | $0.64 |
| Q3 2026 | $0.72 |
Fourth-quarter EPS appears once the press release is read; filings report it only for the full year.
Data
| Q4 2024 | 17.0% |
| Q1 2025 | 12.9% |
| Q2 2025 | 18.4% |
| Q3 2025 | 20.1% |
| Q4 2025 | 25.6% |
| Q1 2026 | 21.4% |
| Q2 2026 | 24.3% |
| Q3 2026 | 24.3% |
Data
| Q4 2024 | $176.8M |
| Q1 2025 | $96.8M |
| Q2 2025 | $208.9M |
| Q3 2025 | $579.4M |
| Q4 2025 | $192.1M |
| Q1 2026 | $449.0M |
| Q2 2026 | $184.5M |
| Q3 2026 | $272.7M |
Operating cash flow minus capital expenditure, from cash flow statements.
| Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | Q3 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.1Bd | $1.0B | $1.2B | $1.2B | $1.3Bd | $1.2B | $1.3B | $1.3B |
| Gross margin | 58.9% | 56.9% | 59.5% | 60.5% | 62.9% | 62.9% | 63.4% | 64.3% |
| Operating income | $188.9Md | $133.7M | $212.6M | $242.5M | $323.0Md | $255.3M | $318.3M | $327.2M |
| Operating margin | 17.0% | 12.9% | 18.4% | 20.1% | 25.6% | 21.4% | 24.3% | 24.3% |
| Net income | $151.7Md | $105.4M | $179.8M | $283.8M | $267.3Md | $199.5M | $249.1M | $275.1M |
| Diluted EPS | — | $0.27 | $0.45 | $0.70 | — | $0.51 | $0.64 | $0.72 |
| Operating cash flow | $301.4Md | $183.8M | $303.0Md | $659.9Md | $294.0Md | $525.6M | $269.2Md | $325.6Md |
| Capital expenditure | $124.6Md | $87.0M | $94.1Md | $80.5Md | $101.9Md | $76.6M | $84.7Md | $52.9Md |
| Free cash flow | $176.8M | $96.8M | $208.9M | $579.4M | $192.1M | $449.0M | $184.5M | $272.7M |
| R&D expense | $139.5Md | $145.2M | $148.2M | $157.5M | $148.2Md | $145.3M | $153.0M | $161.6M |
From XBRL data in 10-Q and 10-K filings. d derived: a fourth quarter is the full year minus the first nine months, and cash flows are year-to-date figures differenced.
10-K and 10-Q filings
- 29 Oct 202610-Q for the period ended 30 Sep 2026SEC ↗
- 30 Jul 202610-Q for the period ended 30 Jun 2026SEC ↗
- 30 Apr 202610-Q for the period ended 31 Mar 2026SEC ↗
- 12 Feb 202610-K for the period ended 31 Dec 2025SEC ↗
- 30 Oct 202510-Q for the period ended 30 Sep 2025SEC ↗
- 30 Jul 202510-Q for the period ended 30 Jun 2025SEC ↗
- 1 May 202510-Q for the period ended 31 Mar 2025SEC ↗
- 18 Feb 202510-K for the period ended 31 Dec 2024SEC ↗